RHHBY — Roche Holding AG
Price when we picked it (May 5, 2026)
$50.84
Target: $60.00 (+18%)
P/E Ratio
19.9
P/E Forward
15.8
Dividend
3.08%
Market Cap
$327.45B
EPS
$2.56
Consensus
Buy
What they do
Roche Holding AG is the oldest company in the global pharmaceutical top tier, founded in 1896 by Fritz Hoffmann-La Roche in Basel, Switzerland. Today it is #1 worldwide in oncology (breast cancer, lymphomas, lung) and #1 worldwide in in-vitro diagnostics (the PCR tests your hospital uses, glucose tests, oncology companion diagnostics). It has two divisions:
**
- Pharma (~78% of revenue) — development and commercialization of medicines. Top products in 2026: Ocrevus (multiple sclerosis), Hemlibra (hemophilia A — first approved bispecific antibody), Vabysmo (macular degeneration and diabetic macular edema), Xolair (severe asthma and allergies), Phesgo (HER2+ breast cancer), Tecentriq (oncology immunotherapy), Evrysdi** (spinal muscular atrophy — the first oral treatment for the disease).
**
- Diagnostics (~22% of revenue) — laboratory tests and medical devices. Roche manufactures the analyzers installed in hospitals in >180 countries. Each year they process >30 billion diagnostic tests** globally.
Ownership structure — the detail that defines everything: Roche has three classes of securities:
- Bearer Shares (ROG.SW) — with voting rights, 12.96% of capital, controlled by the Hoffmann-Oeri family (64.97% of votes via pool created in 1948).
- Genussscheine (Non-Voting Equity Security, NES) — no voting rights, 87.04% of capital, what is bought publicly.
- RHHBY ADR — 8 RHHBY ADRs = 1 Genussschein. RHHBY holders have no voting rights. Economically equivalent to Genussscheine.
The Hoffmann-Oeri family signed a pool agreement in 1948 (76 years ago) that gives them absolute control without needing a majority of the capital. The pool has never sold. Severin Schwan (CEO 2008–2023) and now Thomas Schinecker (CEO since March 2023, formerly CEO of Roche Diagnostics) report to a Board chaired by Christoph Franz (Chairman since 2014). 90 Roche products are on the WHO Essential Medicines List. >100,000 employees globally.
Why we like it
RHHBY at $50.84 means buying the #1 global pharma in oncology and diagnostics at a forward P/E of 15.76x — a discount vs. pharma peers ~18–20x — with a 2026–27 pipeline that carries 3 asymmetric catalysts. Specific reasons:
- Q1 FY2026 beat consensus in both segments (reported April 23, 2026): group revenue CHF 14.722B (+6% CER, +9% USD), Pharma CHF 11.469B (+7% CER), Diagnostics CHF 3.253B (+3% CER). 5 products grew double digits: Ocrevus +6%, Hemlibra +13%, Vabysmo +13%, Xolair +26%, Phesgo +27%. FY2026 guidance confirmed (mid single-digit growth in sales, high single-digit growth in core EPS at CER).
- CT-388 obesity — the most asymmetric bet of the year: Phase 2 results (Sept 2024) showed 22.5% weight loss at 24 weeks vs. ~21% for Mounjaro and ~15% for Wegovy — numbers competitive with the gold standard. Phase 3 just started Q1 2026 (5 simultaneous trials). If CT-388 achieves approval in 2028–29, Roche enters the $150B+ obesity market projected for 2030, currently controlled by Lilly and Novo. Any material capture is massive upside not priced into the stock.
- Trontinemab Alzheimer — 91% reduction of amyloid plaques in Phase 2: unprecedented vs. Lecanemab (Eisai/Biogen) and Donanemab (Lilly) which are in the 60–70% range. Phase 3 starts in 2026, readout ~2028–29. The Alzheimer market is projected at ~$50B+/year.
- 89bio integration (closed Sept 2025, $2.4B + CVR): pegozafermin added the NASH/MASH program (non-alcoholic fatty liver disease) — a category with no approved treatment, ~25% prevalence among U.S. adults. Phase 3 underway.
- Hoffmann-Oeri family control = a 50-year capital allocator: the pool signed in 1948 (76 years ago) guarantees Roche will never be the target of a hostile takeover, will never cut R&D to make a quarter's earnings, will never do financial engineering. Decisions are made with the next generation in mind. It is the longest investment horizon in the global pharma top tier.
- Structural diagnostics moat: Roche manufactures the analyzers installed in >180 countries processing >30B tests/year. Once an analyzer is installed, reagents are a razor-and-blade model for decades.
- Trump–Switzerland 15% tariff cap (vs. 39% original): the Switzerland–U.S. deal of September 2025 caps pharmaceutical tariffs at 15%. Roche committed $50B in U.S. investment over 5 years to neutralize political pressure and maintain access to the world's #1 market.
- 3.08% trailing dividend, 36 consecutive years paid: payout ratio 61%, sustainable. Roche distributes in CHF — Switzerland has 0% withholding tax on U.S. holders of the ADR (treaty).
- Valuation: forward P/E of 15.76x is 15–20% below pharma peers (Lilly 30x, Novo 22x, Pfizer 12x, Merck 14x). If the obesity/Alzheimer/NASH pipeline delivers, a natural re-rating follows. Analyst mean target around $59–62 = +15–20% upside.
Key Risk
The risks are specifically measurable:
- persevERA giredestrant Phase 3 missed its primary endpoint (March 2026) — the oral SERD for ER+ breast cancer post-aromatase inhibitor + CDK4/6 inhibitor failed to beat fulvestrant in first-line metastatic. Roche still has 2 giredestrant studies underway (lidERA adjuvant, evERA combination) but the most anticipated data missed. Any similar failure in CT-388 obesity or trontinemab Alzheimer would be material.
- CT-388 Phase 3 real uncertainty: Phase 2 showed 22.5% weight loss but N=78 patients at 24 weeks. Phase 3 with thousands of patients and 68–78 weeks could reveal side effects that limit dosing or efficacy lower than peers. If CT-388 fails, the asymmetric obesity thesis disappears.
- Trontinemab Alzheimer — Phase 2 was impressive but small N: 91% amyloid plaque reduction is unprecedented but Phase 3 must show cognition/function impact. The Lecanemab + Donanemab precedent shows that reducing plaques doesn't always translate to meaningful clinical benefit.
- U.S. pharmaceutical tariffs: the 15% cap post-deal is a reduction from the 39% original but still a cost. Roche has 36% of revenue in the U.S. ($21B of $58B in 2024). Every additional 1% tariff = ~$200M/year. If the Trump administration changes terms, there is risk.
- 89bio integration: $3.5B total deal with CVR — if pegozafermin NASH fails in Phase 3, Roche writes off goodwill.
- Patent cliffs 2026–29: Ocrevus loses U.S. exclusivity in 2029 (CHF 7B+ product in 2025); biosimilars will enter. Hemlibra protected through 2028+. Tecentriq biosimilars starting ~2027.
- Non-voting ADR structure: RHHBY holders do not participate in corporate governance. If the Hoffmann-Oeri family made a decision that harmed the public float, there is no defense. Historically aligned but structurally possible.
- CHF/USD currency risk: Roche reports in CHF. If CHF appreciates vs. USD, USD-denominated revenue reported in CHF falls even if volumes grow.
- Diagnostics competition from China: Mindray, Sysmex, Siemens Healthineers gaining share in emerging markets. Diagnostics only grew +3% in Q1 2026 (vs. Pharma +7%). (10) Government drug pricing pressure: the Inflation Reduction Act (IRA) Medicare price negotiation is expanding its list of drugs — Ocrevus could be included in 2027–28.
This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.
Vectorial Data picked RHHBY on May 5, 2026 at $50.84.
Full Research
Roche Holding AG (RHHBY) — Full Research
Price: $50.84 | P/E TTM: 19.86 | Forward P/E: 15.76 | Div Yield: 3.08% | Market Cap: $327.45B
What is Roche?
Roche Holding AG is the oldest company in the global pharmaceutical top tier, founded in 1896 by Fritz Hoffmann-La Roche in Basel, Switzerland. Today it is:
- #1 globally in oncology (breast cancer, lymphomas, lung)
- #1 globally in in-vitro diagnostics (>180 countries, >30B tests/year)
- 130 years of continuous history controlled by the same founding family
Ownership Structure — The Detail That Defines Everything
Roche has three classes of securities:
| Security | Voting | % of Capital | Who holds it |
|---|---|---|---|
| Bearer Shares (ROG.SW) | Yes | 12.96% | Hoffmann-Oeri family (64.97% of votes via 1948 pool) |
| Genussscheine (NES) | No | 87.04% | Global public float |
| RHHBY ADR | No | (represents Genussschein) | 8 ADRs = 1 Genussschein |
The Hoffmann-Oeri family pool signed in 1948 (76 years ago) guarantees absolute control. The family has never sold. RHHBY investors have no voting rights, but are economically equivalent to Genussscheine holders.
Q1 FY2026 — Reported April 23, 2026
| Metric | Q1 2026 | YoY (CER) |
|---|---|---|
| Group revenue | CHF 14.722B | +6% CER, +9% USD |
| Pharma | CHF 11.469B | +7% CER |
| Diagnostics | CHF 3.253B | +3% CER |
Top 5 growing products Q1:
- Ocrevus (multiple sclerosis): CHF 1.69B (+6%)
- Hemlibra (hemophilia A): CHF 1.19B (+13%)
- Vabysmo (macular degeneration): CHF 1.02B (+13%)
- Xolair (asthma/allergies): CHF 708M (+26%)
- Phesgo (HER2+ breast cancer): CHF 686M (+27%)
FY2026 guidance confirmed: mid single-digit growth in sales, high single-digit growth in core EPS at CER.
Pipeline 2026–29 — The 3 Asymmetric Bets
(1) CT-388 — Obesity (Phase 3 initiating Q1 2026)
- Phase 2 result (Sept 2024): 22.5% weight loss at 24 weeks
- Comparison: Mounjaro ~21%, Wegovy ~15%
- Phase 3: 5 simultaneous trials underway
- Obesity market: $150B+ projected for 2030 (today ~$30B)
- Expected approval: 2028–29 if Phase 3 confirms data
(2) Trontinemab — Alzheimer (Phase 3 initiating 2026)
- Phase 2 result (Oct 2024): 91% reduction of amyloid plaques
- Comparison: Lecanemab (Eisai) ~60%, Donanemab (Lilly) ~70%
- Phase 3 readout: ~2028–29
- Alzheimer market: $50B+/year projected
(3) Pegozafermin (89bio) — NASH/MASH
- 89bio acquisition closed Sept 2025: $2.4B + CVR up to $6/sh = ~$3.5B total
- NASH/MASH: non-alcoholic fatty liver disease, no approved treatment, ~25% prevalence among U.S. adults
- Phase 3 underway
Tariffs and Policy — Trump–Switzerland Deal
- 15% tariff cap (down from 39% original) after the Switzerland–U.S. deal in September 2025
- Roche committed $50B in U.S. investment over 5 years
- 36% of Roche revenue comes from the U.S. ($21B of $58B in 2024)
- Every additional 1% of tariff = ~$200M/year
Capital Return
- Dividend CHF 9.80/Genussschein FY2025 (USD ADR yield ~3.08%)
- 36 consecutive years of paying/raising the dividend
- Payout ratio: 61%
- Buybacks: limited — Roche prefers to reinvest in R&D + M&A
- Switzerland–U.S. 0% withholding tax on RHHBY ADR (treaty)
Patent Landscape
| Product | Loses Exclusivity |
|---|---|
| Ocrevus | U.S. 2029 (~CHF 7B in 2025) |
| Hemlibra | 2028+ |
| Tecentriq | ~2027 (biosimilars) |
| Vabysmo | 2032+ |
| Phesgo | 2030+ |
Upcoming Catalysts
- Q2 FY2026 earnings: ~July 24, 2026
- CT-388 Phase 3 initial readouts: 2027
- Trontinemab Phase 3 enrollment: completes 2026
Thesis in One Line
Buy the #1 global pharma in oncology and diagnostics at a forward P/E of 15.76x, with the Hoffmann-Oeri family in control for 76 years (multi-generational capital allocator), a 2026–29 pipeline with 3 asymmetric bets (CT-388 obesity, trontinemab Alzheimer, pegozafermin NASH), the Trump–Switzerland 15% tariff cap, and a 3.08% dividend / 36 consecutive years.
Research date: May 5, 2026 | Next review: Nov 2026
This is not financial advice.
More picks in Healthcare
- BDX — Becton Dickinson
- ZTS — Zoetis Inc
- GILD — Gilead Sciences
- HCA — HCA Healthcare, Inc.
- DHR — Danaher Corporation
- GSK — GSK plc
More picks from Switzerland
See all picks from Switzerland →This is not financial advice. Consult a certified financial advisor.
The author may hold positions in the securities discussed.
Past performance does not guarantee future results.